FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974769159> ?p ?o ?g. }

• W1974769159 endingPage "1342" @default.
• W1974769159 startingPage "1335" @default.
• W1974769159 abstract "New aromatase inhibitors (AI) (second-generation: formestane and fadrozole; third-generation: letrozole, anastrozole, vorozole, and exemestane) have been tested in several controlled clinical trials after tamoxifen failure in metastatic breast carcinoma (MBC). They have resulted in better survival compared with megestrol acetate (MEG) in a number of studies. The authors performed a pooled analysis including all the Phase III trials published between 1996 and 2004 evaluating the AIs approved or not by the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medical Products (EMEA) as second-line endocrine therapy (ET) for patients with MBC.The overall response rate (ORR) and time to disease progression (TTP) were considered the primary end points, whereas toxicity was regarded as a secondary objective. Relative risk, 95% confidence interval, and heterogeneity were derived using 2 methods.No significant differences in ORR and TTP were noted in the entire group of 9 trials comparing AI with MEG (3908 patients) and in the 6 trials comparing nonsteroidal AI and MEG (2415 patients). AI yielded significantly more hot flashes than MEG (P = 0.004) but caused significantly less toxicity than MEG in weight gain (P = 0.001), dyspnea (P = 0.008), and peripheral edema (P = 0.03). Significant heterogeneity for nausea, weight gain, dyspnea, and peripheral edema was registered. When steroidal AIs were excluded from the toxicity analysis, nausea maintained its strongly significant heterogeneity (P = 0.0002), whereas weight gain, dyspnea, and peripheral edema lost their significance.This pooled analysis suggested that AIs in second-line ET for patients with MBC do not seem to add any significant benefit to MEG in terms of ORR and TTP. With regard to toxicity, the findings in the current study showed that weight gain, dyspnea, and peripheral edema are more frequent with the use of MEG, whereas hot flashes were more represented using AI." @default.
• W1974769159 created "2016-06-24" @default.
• W1974769159 creator A5001910485 @default.
• W1974769159 creator A5020732852 @default.
• W1974769159 creator A5023710153 @default.
• W1974769159 creator A5023848359 @default.
• W1974769159 creator A5025381371 @default.
• W1974769159 creator A5039867262 @default.
• W1974769159 creator A5042436465 @default.
• W1974769159 creator A5045496715 @default.
• W1974769159 creator A5045603955 @default.
• W1974769159 creator A5052556729 @default.
• W1974769159 creator A5061240925 @default.
• W1974769159 creator A5072619943 @default.
• W1974769159 creator A5086199413 @default.
• W1974769159 creator A5086743021 @default.
• W1974769159 date "2005-10-01" @default.
• W1974769159 modified "2023-09-24" @default.
• W1974769159 title "New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma" @default.
• W1974769159 cites W1453600927 @default.
• W1974769159 cites W1562190372 @default.
• W1974769159 cites W1563102200 @default.
• W1974769159 cites W1839333839 @default.
• W1974769159 cites W1918073772 @default.
• W1974769159 cites W1932574503 @default.
• W1974769159 cites W1934173384 @default.
• W1974769159 cites W1939805819 @default.
• W1974769159 cites W1989190673 @default.
• W1974769159 cites W2013657890 @default.
• W1974769159 cites W2014001882 @default.
• W1974769159 cites W2032092237 @default.
• W1974769159 cites W2046794494 @default.
• W1974769159 cites W2054702701 @default.
• W1974769159 cites W2059216229 @default.
• W1974769159 cites W2075642745 @default.
• W1974769159 cites W2088064703 @default.
• W1974769159 cites W2101881391 @default.
• W1974769159 cites W2108533813 @default.
• W1974769159 cites W2132846837 @default.
• W1974769159 cites W2137131274 @default.
• W1974769159 cites W2144449199 @default.
• W1974769159 cites W2151970467 @default.
• W1974769159 cites W2163688875 @default.
• W1974769159 cites W2202169216 @default.
• W1974769159 cites W2242258808 @default.
• W1974769159 cites W2327085958 @default.
• W1974769159 cites W4300776185 @default.
• W1974769159 doi "https://doi.org/10.1002/cncr.21339" @default.
• W1974769159 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16088965" @default.
• W1974769159 hasPublicationYear "2005" @default.
• W1974769159 type Work @default.
• W1974769159 sameAs 1974769159 @default.
• W1974769159 citedByCount "32" @default.
• W1974769159 countsByYear W19747691592012 @default.
• W1974769159 countsByYear W19747691592013 @default.
• W1974769159 countsByYear W19747691592014 @default.
• W1974769159 countsByYear W19747691592015 @default.
• W1974769159 countsByYear W19747691592018 @default.
• W1974769159 countsByYear W19747691592019 @default.
• W1974769159 countsByYear W19747691592020 @default.
• W1974769159 countsByYear W19747691592022 @default.
• W1974769159 crossrefType "journal-article" @default.
• W1974769159 hasAuthorship W1974769159A5001910485 @default.
• W1974769159 hasAuthorship W1974769159A5020732852 @default.
• W1974769159 hasAuthorship W1974769159A5023710153 @default.
• W1974769159 hasAuthorship W1974769159A5023848359 @default.
• W1974769159 hasAuthorship W1974769159A5025381371 @default.
• W1974769159 hasAuthorship W1974769159A5039867262 @default.
• W1974769159 hasAuthorship W1974769159A5042436465 @default.
• W1974769159 hasAuthorship W1974769159A5045496715 @default.
• W1974769159 hasAuthorship W1974769159A5045603955 @default.
• W1974769159 hasAuthorship W1974769159A5052556729 @default.
• W1974769159 hasAuthorship W1974769159A5061240925 @default.
• W1974769159 hasAuthorship W1974769159A5072619943 @default.
• W1974769159 hasAuthorship W1974769159A5086199413 @default.
• W1974769159 hasAuthorship W1974769159A5086743021 @default.
• W1974769159 hasConcept C121608353 @default.
• W1974769159 hasConcept C126322002 @default.
• W1974769159 hasConcept C143998085 @default.
• W1974769159 hasConcept C197934379 @default.
• W1974769159 hasConcept C2775930923 @default.
• W1974769159 hasConcept C2776215463 @default.
• W1974769159 hasConcept C2777176818 @default.
• W1974769159 hasConcept C2777482430 @default.
• W1974769159 hasConcept C2778812593 @default.
• W1974769159 hasConcept C29730261 @default.
• W1974769159 hasConcept C530470458 @default.
• W1974769159 hasConcept C71924100 @default.
• W1974769159 hasConcept C90924648 @default.
• W1974769159 hasConceptScore W1974769159C121608353 @default.
• W1974769159 hasConceptScore W1974769159C126322002 @default.
• W1974769159 hasConceptScore W1974769159C143998085 @default.
• W1974769159 hasConceptScore W1974769159C197934379 @default.
• W1974769159 hasConceptScore W1974769159C2775930923 @default.
• W1974769159 hasConceptScore W1974769159C2776215463 @default.
• W1974769159 hasConceptScore W1974769159C2777176818 @default.
• W1974769159 hasConceptScore W1974769159C2777482430 @default.
• W1974769159 hasConceptScore W1974769159C2778812593 @default.

• next